McKesson Corporation vs Quanta Services Inc — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while Quanta Services Inc trades at $693 (market cap $103.03B). The key difference: McKesson Corporation and Quanta Services Inc are close in size by market cap, and McKesson Corporation pays the higher dividend (0.4%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Quanta Services Inc for 62 Days on average.
| MCK | PWR | |
|---|---|---|
Market Cap | $108.46B | $103.03B |
Volume | 712,607 | 977,892 |
Sector | Health | Industrials |
52-Week High | $995.69 | $785.24 |
52-Week Low | $725.17 | $412.21 |
Typical Hold Time | 74 Days | 62 Days |
Enterprise Value | $115.00B | $109.13B |
Dividend Yield | 0.4% | 0.06% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Quanta Services (PWR) trades at $701.07, down 2.57% on the day, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $4.24 surpassing the $3.31 forecast. Revenue growth is robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins remain modest at 4.03%. A record $53B backlog and positive media coverage on AI infrastructure demand highlight operational strength.
The investment outlook is positive, driven by earnings momentum and sector tailwinds, but high valuation multiples (P/E 80.21) and execution risks on large projects pose challenges. The consensus price target of $802.08 implies significant upside, supported by 27 buy ratings and no sell recommendations from analysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →